MedTrace Logo

Anticoagulation in Emergency General Surgery

NCT04216394 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4

Last updated 2026-03-27

No results posted yet for this study

Summary

While DOACs are increasing in use in the EGS patient population, the risk of bleeding and the reversal of these agents to reduce hemorrhage is still evolving. Given the paucity of data regarding the impact of DOACs in this patient population, it becomes empiric to identify bleeding patterns and outcomes in the EGS population taking DOACs. We hypothesize that patients taking a DOAC will have a higher bleeding incidence and need for an unplanned intervention secondary to hemorrhage in EGS patients undergoing an urgent or emergent operation when compared to patients taking warfarin and antiplatelets.

Conditions

  • Emergency General Surgery

Interventions

PROCEDURE

Emergency general surgery

multidisciplinary surgery performed for traumatic and non-traumatic acute conditions during the same admission in the hospital.

Sponsors & Collaborators

  • Methodist Health System

    lead OTHER

Principal Investigators

  • Michael Truitt, MD · Methodist Dallas Medical Center Trauma

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-31
Primary Completion
2020-11-13
Completion
2020-11-13

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04216394 on ClinicalTrials.gov